Global Esophageal Cancer Market Spotlight 2017-2026: Roche and Sanofi Lead Industry Sponsors with the Highest Number of Clinical Trials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Esophageal Cancer” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the esophageal cancer market,
comprising key marketed and pipeline drugs, patent information, a
10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways:

• The report estimates that in 2017, there were 488,800 incident cases
  of esophageal cancer worldwide, and expects that number to increase to
  534,700 incident cases by 2026.
• Incidence is higher in males compared to females, and is highest in
  the Asia region. Photofrin, a two-step therapy that involves the
  injection of the photoactive drug followed by drug activation using
  laser therapy, is the only FDA-approved drug for esophageal cancer.
• The majority of industry-sponsored drugs in active clinical
  development for esophageal cancer are in Phase II. Therapies in
  development for esophageal cancer focus on a wide variety of targets.
  The majority of pipeline drugs in mid-to-late stage development are
  administered intravenously, with three drugs being tested in oral
  formulations.
• The only high-impact upcoming event in the esophageal cancer space is
  topline Phase III trial results for Opdivo. The overall likelihood of
  approval of a Phase I solid tumor asset is 5.7%, and the average
  probability a drug advances from Phase III is 39.4%. Drugs, on
  average, take 9.5 years from Phase I to approval, compared to 9.2
  years in the overall oncology space.
• There have been 10 licensing and asset acquisition deals involving
  esophageal cancer drugs during 2014-19. The $1,456m drug development
  collaboration agreement signed in 2015 between Eli Lilly and Innovent
  Biologics to support the development and potential commercialization
  of at least three cancer treatments was the largest deal.
• The distribution of clinical trials across Phase I-IV indicates that
  the vast majority of trials for esophageal cancer have been in the
  early and mid-phases of development, with 91% of trials in Phase I-II,
  and only 9% in Phase III-IV.
• The US has a substantial lead in the number of esophageal cancer
  clinical trials globally. The UK leads the major EU markets, while
  Japan has the top spot in Asia.
• Clinical trial activity in the esophageal cancer space is dominated by
  completed trials. Sanofi has the highest number of completed clinical
  trials for esophageal cancer, with 89 trials.
• Roche and Sanofi lead industry sponsors with the highest number of
  clinical trials for esophageal cancer.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Surgery

Radiation therapy

Endoscopic therapy

Chemotherapy

Targeted therapy

Immunotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Keytruda for Esophageal Cancer (January 14, 2019)

Opdivo for Esophageal Cancer (January 9, 2019)

Keytruda for Esophageal Cancer (November 14, 2018)

Keytruda for Esophageal Cancer (June 3, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/y5j2rg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs